How I use fibrinogen replacement therapy in acquired bleeding
Top Cited Papers
Open Access
- 26 February 2015
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 125 (9) , 1387-1393
- https://doi.org/10.1182/blood-2014-08-552000
Abstract
Fibrinogen is a critical protein for hemostasis and clot formation. However, transfusion guidelines have variable recommendations for maintaining fibrinogen levels in bleeding patients. An increasing number of studies support the practice of fibrinogen replacement therapy for acquired coagulopathies, and additional studies are underway. Fibrinogen therapy can be administered with cryoprecipitate or fibrinogen concentrates, and clinical practice varies according to their availability and licensing status. Fibrinogen concentrate therapy has been studied in animal models and clinical trials, and support the critical role of fibrinogen repletion in bleeding patients. Point-of-care testing will have an important role in guiding fibrinogen replacement for hemostatic therapy in clinical settings such as cardiovascular surgery, postpartum hemorrhage, and trauma. Fibrinogen therapy is an important component of a multimodal strategy for the treatment of coagulopathic bleeding.This publication has 99 references indexed in Scilit:
- Estimation of plasma fibrinogen levels based on hemoglobin, base excess and Injury Severity Score upon emergency room admissionCritical Care, 2013
- Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgeryBritish Journal of Anaesthesia, 2013
- The FIB-PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trialTrials, 2012
- Early and individualized goal-directed therapy for trauma-induced coagulopathyScandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2012
- Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapyCritical Care, 2011
- The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trialThe Lancet, 2011
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialThe Lancet, 2010
- Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgeryBritish Journal of Anaesthesia, 2010
- Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot studyBritish Journal of Anaesthesia, 2009
- Incidence of severe pre‐eclampsia, postpartum haemorrhage and sepsis as a surrogate marker for severe maternal morbidity in a European population‐based study: the MOMS‐B surveyBJOG: An International Journal of Obstetrics and Gynaecology, 2004